stockrowViridian Therapeutics, Inc.
VRDN Healthcare Biotechnology
Viridian Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.8 million, up 23,359.9% from fiscal 2024.
- Revenue
- −63.5%
- EPS
- −5.00%
- Free cash flow
- −9.92%
- Total debt
- +1,064.9%
Quarter to September 2026, against a year earlier
Follow VRDN
Alert me
Viridian Therapeutics, Inc. (VRDN) Revenue
Viridian Therapeutics, Inc.'s revenue for fiscal 2025 was $70.8M, up 23,359.9% from $302.0K in fiscal 2024. Over the twelve months to 30 September 2026 it was $26.3M. Over the past ten years it has ranged from $302.0K (fiscal 2024) to $70.8M (fiscal 2025) — the current reading is the highest in ten years. Viridian Therapeutics, Inc. ranks 170th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $70.8M | 23,359.93% |
| FY2024 | $302.0K | (3.82%) |
| FY2023 | $314.0K | (82.28%) |
| FY2022 | $1.8M | (40.20%) |
| FY2021 | $3.0M | 182.19% |
| FY2020 | $1.1M | (76.46%) |
| FY2019 | $4.5M | (46.80%) |
| FY2018 | $8.4M | 109.49% |
| FY2017 | $4.0M | 15.13% |
| FY2016 | $3.5M | 37.00% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $25.8M | 8,967.61% |
| Jun 2026 | $284.0K | 101.42% |
| Mar 2026 | $141.0K | 6.82% |
| Dec 2025 | $132.0K | (99.81%) |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| TARS Tarsus Pharmaceuticals, Inc. compare | $682.2M |
| IDYA IDEAYA Biosciences, Inc. compare | $36.5M |
| VRDN Viridian Therapeutics, Inc. | $26.3M |
| DNLI Denali Therapeutics Inc. compare | $22.6M |
| VKTX Viking Therapeutics, Inc. compare | — |
| TLX Telix Pharmaceuticals Limited compare | — |
| CELC Celcuity, Inc. compare | — |
| DYN Dyne Therapeutics, Inc. compare | — |
| ELVN Enliven Therapeutics, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on VRDN
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement